In the combined Munich and Aberdeen discovery cohort, the MAF of rs2135551 was 0.23 in cases and 0.30 in controls. In the Italian cohort, the MAF was a little higher at 0.33 in cases and 0.36 in controls, in Iceland the MAF was 0.25 in cases and 0.27 in controls, and in the European-American sample it was 0.28 in cases and 0.25 in controls. These data indicate that despite its real functional effect, the top association with schizophrenia in the discovery and first replication cohorts is likely to be a false positive.
